Why Are Xeris Biopharma Shares Moving Monday?
Portfolio Pulse from Dylan Berman
Xeris Biopharma Holdings, Inc (NASDAQ:XERS) shares rose after announcing a worldwide collaboration and license agreement with Beta Bionics to develop and release a glucagon product using Xeris's XeriSol technology. The agreement includes potential development payments and royalties for Xeris. The company is also set to release its Q1 2024 earnings, with an expected EPS loss of 12 cents and revenue of $41.815 million.
May 06, 2024 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xeris Biopharma's stock rose following the announcement of a collaboration with Beta Bionics to develop a glucagon product, indicating potential future revenue through development payments and royalties.
The positive movement in Xeris's stock price is directly attributed to the announcement of the collaboration with Beta Bionics, which opens up new revenue streams through development payments and royalties. The anticipation of the Q1 2024 earnings report also plays a role in investor sentiment, despite the expected EPS loss, as it provides insight into the company's financial health and future prospects.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100